Eze/Simva Switch Study in Diabetics (0653A-807)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

648 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-19

Study Completion Date

2005-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to assess the effectiveness and tolerability of MK0653A and MK0653A versus Atorvastatin in lowering LDL-C levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

NCT03885921

Hypercholesterolemia

COMPLETED PHASE3

A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)

NCT00652301

Cholesterol

COMPLETED PHASE3

Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)

NCT03867318

Hypercholesterolemia

COMPLETED PHASE3

Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Function

NCT00189085

Metabolic Syndrome

COMPLETED PHASE4

The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study

NCT00817843

Metabolic Syndrome

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks

Intervention Type DRUG

Comparator: atorvastatin / Duration of Treatment: 6 Weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Currently being treated with Atorvastatin 10 mg for at least 6 weeks
* Have Type 2 Diabetes
* Weight must be stable for more than 6 weeks before entering the study

Exclusion Criteria

* Consume more than 14 alcoholic drinks per week.
* Pregnant or lactating
* Have taken another investigation drug within 3 months of starting this study
* History of congestive heart failure, heart attack, coronary artery bypass surgery
* Uncontrolled high blood pressure
* HIV positive
* History of cancer in the last 5 years

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No